Nontuberculous Mycobacterium (NTM) pulmonary disease is a growing global health concern and major unmet medical need due to a lack of new medications being developed to combat these bacteria.
SPR720 is a broad spectrum, oral candidate that, if approved, may be applicable to both non-refractory and refractory patients. Once daily dosing is supported by clinical and non-clinical studies.
Follow the progress of SPR720 as the candidate moves through clinical trials at ClinicalTrials.gov
Chemical Formula: C21H25FN6NaO6P
Molecular Weight: 530.43g/mol
Spero Therapeutics is developing SPR720, a novel, investigational oral agent to treat NTM pulmonary disease.
SPR720 is an orally administered investigational antibacterial agent being developed for the treatment of NTM pulmonary disease. If approved, SPR720 will represent a novel class of antibacterial agents that target enzymes essential for bacterial DNA replication.
The clinical development of SPR720 is supported by data from its first-in-human Phase 1 clinical trial of SPR720 in healthy volunteers and pharmacokinetic / pharmacodynamic data that suggested predicted therapeutic exposures could be attained with a 500 – 1,000 mg once daily oral dose. Pre-clinical in vitro and in vivo studies have demonstrated potency for SPR720 against Mycobacterium tuberculosis (TB) and a range of bacteria that cause NTM infections, including mycobacterium avium complex, mycobacterium kansasii and mycobacterium abscessus.
Designed to improve lives of patients suffering from NTM
SPR720 may fill an urgent void for a new suite of drugs that can be used in combination to arrest NTM infection, and possibly prevent the lung damage that infection causes.
September 1, 2023 - Phase 2A Study SPR720--202 is posted to ClincialTrials.gov. Enrollment began in Q4 2022 with top line data expected in 2H 2024.
The Phase 2A SPR720 study is designed to evaluate the efficacy, safety, tolerability and pharmacokinetic of SPR720, as compared with placebo for the treatment of participants with Mycobacterium avium complex (MAC) pulmonary disease.
There is a growing population of older NTM patients, some of them have underlying immunosuppressive disease or chronic progressive pulmonary disease, without adequate treatment. This is a huge clinical void right now. There’s nothing in that space, and patients are desperate for new treatment.
Tim Keutzer
Chief Development Officer
SPR720 is a broad spectrum, oral candidate that, if approved, may be applicable to both non-refractory and refractory patients. Once daily dosing is supported by clinical and non-clinical studies.
In NTM, treatment failure is common and the current treatment for NTM is lengthy and involves combination therapy, often including three or more antibiotics, including injectables.
NTM Info & Research is a 501(c)(3) non-profit organization formed for patient support, medical education and to help accelerate research.
Patients can follow the progress of SPR720 as the candidate moves through clinical trials. ClinicalTrials.gov is a database of clinical studies conducted worldwide.
(Blog post authored by Ankit Mahadevia)
